Sinetrol (Citrus sinensis/Citrus paradisi extract)

Sinetrol is a patented citrus polyphenol extract derived from Citrus sinensis and Citrus paradisi, standardized for naringenin, hesperidin, neohesperidin, and caffeine. Its primary mechanism involves inhibition of phosphodiesterase-3 (PDE-3), which elevates intracellular cAMP and drives lipolysis in adipose tissue.

Origin & History

Sinetrol is a patented polyphenol-rich extract derived from Mediterranean citrus fruits including sweet orange (Citrus sinensis), blood orange, grapefruit (Citrus paradisi), and guarana (Paullinia cupana). It is produced through physical processes including crushing, cold-pressing, extraction, centrifugation, filtration, and spray-drying of fruit juice, peels, and seeds, yielding a natural combination standardized to contain up to 90% polyphenols.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for Sinetrol, as it is a modern patented ingredient explicitly designed as a 'unique Mediterranean weight-loss' formula. The product was inspired by the polyphenol-rich Mediterranean diet rather than any specific traditional medicine system.

Health Benefits

• Reduces body fat mass while preserving lean muscle mass (clinical trials on Asian and Caucasian subjects)
• Decreases waist and hip circumference measurements (2015 French trial with 630 mg/day Sinetrol-XPur)
• Enhances lipolysis by 2.8-fold through PDE-3 inhibition (Dallas et al., Phytomedicine 2008, p<0.05)
• Promotes adipose tissue beiging to increase resting energy expenditure (mechanism studies)
• Provides non-thermogenic weight management without stimulant effects (100% weight loss from fat mass vs placebo)

How It Works

Sinetrol inhibits phosphodiesterase-3 (PDE-3) in adipocytes, preventing the degradation of cyclic AMP (cAMP) and thereby sustaining protein kinase A (PKA) activation, which phosphorylates hormone-sensitive lipase (HSL) to mobilize stored triglycerides. This cascade produces a 2.8-fold increase in lipolytic activity compared to control, as measured by glycerol release in isolated adipocytes (Dallas et al., Phytomedicine 2008). The polyphenols naringenin and hesperidin are considered the primary bioactive drivers of PDE inhibition, while the naturally present caffeine may contribute synergistically through adenosine receptor antagonism.

Scientific Research

Clinical evidence includes the Dallas et al. (Phytomedicine 2008) study demonstrating potent lipolytic activity via 97% PDE inhibition and 2.8-fold increase in free fatty acid release. A 2015 French human trial on Sinetrol-XPur (630 mg/day) reported significant abdominal fat, waist, and hip reductions in men, though specific PMIDs for direct Sinetrol RCTs were not provided in available data. Fytexia cites trials showing 100% weight loss from fat mass using 2x450 mg/day protocols with Harris-Benedict individualized intakes.

Clinical Summary

A 2015 randomized, double-blind, placebo-controlled French trial (n=95 overweight adults) using 630 mg/day Sinetrol-XPur for 12 weeks demonstrated significant reductions in body fat mass, waist circumference, and hip circumference versus placebo. Separate trials enrolling both Asian and Caucasian cohorts confirmed reductions in total body fat percentage while lean muscle mass was preserved, suggesting a selective lipolytic action without catabolism. Dallas et al. (2008, Phytomedicine) documented the 2.8-fold lipolysis enhancement in vitro and supported the PDE-3 mechanism. Overall evidence quality is moderate—trials are industry-sponsored, relatively short in duration, and use small-to-medium sample sizes, warranting independent replication.

Nutritional Profile

Sinetrol is a standardized polyphenol-rich extract derived from sweet orange (Citrus sinensis) and grapefruit (Citrus paradisi) pulp, not a whole food ingredient, so macronutrient content is negligible at functional doses. Bioactive composition is characterized primarily by flavanones and flavones: naringin (from grapefruit, typically 15–30% of extract by weight), hesperidin (from sweet orange, typically 10–25%), neohesperidin, narirutin, and didymin. The XPur commercial form is standardized to ≥60% total polyphenols by dry weight. Also contains hydroxycinnamic acids including caffeic acid and p-coumaric acid at minor concentrations (<5%). Carotenoids (beta-cryptoxanthin, zeaxanthin) are present in trace amounts from the fruit pulp matrix. Vitamin C content is negligible after extraction processing. No meaningful protein, fat, or dietary fiber content at the 300–630 mg/day functional dose range used in clinical trials. Bioavailability: Flavanones undergo hydrolysis by colonic microbiota to yield aglycone forms (naringenin, hesperetin), which are the primary absorbed species; peak plasma concentrations of naringenin reach approximately 0.5–1.5 µmol/L following typical doses. The polyphenol matrix exhibits synergistic PDE-3 inhibitory activity not attributable to single isolated compounds, indicating bioactivity is concentration- and matrix-dependent.

Preparation & Dosage

Clinically studied dosage: 630 mg/day of Sinetrol-Xpur C, taken as either 2x450 mg/day capsules or 1x900 mg/day tablets. Standardization includes >40% flavanones (naringin, hesperidin) and 3.5% caffeine. Some formulations contain 60% total polyphenols, 16.7% flavanones, 2% anthocyanins, and 3.6% caffeine. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, L-carnitine, conjugated linoleic acid (CLA), chromium picolinate, forskolin

Safety & Interactions

Sinetrol is generally well tolerated at studied doses (630–900 mg/day), with no serious adverse events reported in published clinical trials lasting up to 12 weeks. Because it contains naturally occurring caffeine, individuals sensitive to stimulants may experience mild insomnia, increased heart rate, or jitteriness, particularly when combined with other caffeine-containing products. Naringenin, a key constituent, is a known inhibitor of cytochrome P450 enzymes CYP3A4 and CYP1A2, which could theoretically raise plasma levels of medications metabolized by these pathways, including statins, calcium channel blockers, and certain immunosuppressants—similar to grapefruit drug interactions. Safety data in pregnant or breastfeeding women and in pediatric populations is absent, and use in these groups should be avoided until evidence is available.